Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Purpose TFE3-rearranged/TFEB-altered renal cell carcinoma (RCC) is a rare subtype of RCC. Due to its rarity, there is an unmet medical need for effective therapies in advanced settings. The study aims to investigate the clinical and histopathological characteristics of patients with microphthalmia t...

ver descrição completa

Detalhes bibliográficos
Principais autores:	Joohyun Hong, Ghee Young Kwon, Minyong Kang, Seong Il Seo, Se Hoon Park
Formato:	Artigo
Idioma:	English
Publicado em:	Korean Urological Oncology Society 2024-03-01
coleção:	Journal of Urologic Oncology
Assuntos:	-rearranged -altered renal cell carcinoma tyrosine kinase inhibitors immune checkpoint inhibitors
Acesso em linha:	http://www.e-juo.org/upload/pdf/juo-234600660033.pdf

Registros relacionados

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
por: Huang JT, et al.
Publicado em: (2022-11-01)

Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience
por: Pan X, et al.
Publicado em: (2023-06-01)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Fei Yang, et al.
Publicado em: (2022-01-01)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
por: Hongyu Pan, et al.
Publicado em: (2025-03-01)

Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors
por: A. Yu. Goryainova, et al.
Publicado em: (2021-12-01)

Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Gao B, et al.
Publicado em: (2023-12-01)

Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors
por: Ning Luo, et al.
Publicado em: (2023-08-01)

Additive toxicity arising from combined use of immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with renal or endometrial carcinoma: Protocol for a rapid systematic review
por: Shannon E. Kelly, et al.
Publicado em: (2024-06-01)

Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study
por: Guosheng Yuan, et al.
Publicado em: (2024-03-01)

Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?
por: Sang Youn Hwang, et al.
Publicado em: (2023-11-01)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Christopher Kwok, et al.
Publicado em: (2023-07-01)

Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study
por: Junfeng Bu, et al.
Publicado em: (2025-02-01)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
por: Karam Khaddour, et al.
Publicado em: (2020-10-01)

Prognostic value of platelet-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization and tyrosine kinase inhibitors plus immune checkpoints inhibitors
por: Yiwan Guo, et al.
Publicado em: (2024-01-01)

Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis
por: David O’Reilly, et al.
Publicado em: (2024-07-01)

Advances in MET tyrosine kinase inhibitors in gastric cancer
por: Yifan Zhang, et al.
Publicado em: (2024-06-01)

Prognostic value of the neutrophil-to-lymphocyte ratio and prognostic nutritional index in unresectable hepatocellular carcinoma patients treated with tyrosine kinase inhibitors and immune checkpoint inhibitors
por: Shasha Sun, et al.
Publicado em: (2024-12-01)

Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors
por: Emmy D. G. Fleuren, et al.
Publicado em: (2021-11-01)

Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report
por: Jian Wang, et al.
Publicado em: (2024-12-01)

Interventional therapy combined with tyrosine kinase inhibitors with or without immune checkpoint inhibitors as initial treatment for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis
por: Changjie Du, et al.
Publicado em: (2024-05-01)

A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
por: Renguo Guan, et al.
Publicado em: (2022-09-01)

Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
por: Yuhang Chen, et al.
Publicado em: (2024-12-01)

The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
por: Qiao Ke, et al.
Publicado em: (2022-05-01)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
por: Ling Peng, et al.
Publicado em: (2022-04-01)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Yue Chen, et al.
Publicado em: (2022-06-01)

Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization
por: Halil Ibrahim Onder, et al.
Publicado em: (2014-04-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
por: Ichiro Yamauchi, et al.
Publicado em: (2025-01-01)

Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor
por: Daniela R. Montagna, et al.
Publicado em: (2022-08-01)

Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
por: Pottayil G. Sasikumar, et al.
Publicado em: (2020-12-01)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
por: Ryo Ariyasu, MD, et al.
Publicado em: (2023-06-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
por: Yi-fan Chen, et al.
Publicado em: (2011-12-01)

A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study
por: Kexue Deng, et al.
Publicado em: (2022-09-01)

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis
por: Jingyang Su, et al.
Publicado em: (2024-04-01)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
por: Eva Zhang, et al.
Publicado em: (2021-05-01)

Recent Advances in Immune Checkpoint Inhibitor-associated Pneumonitis
por: CHEN Shuangqing, et al.
Publicado em: (2022-10-01)

A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature
por: Qi Zhu, et al.
Publicado em: (2022-05-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
por: Hanping Wang, et al.
Publicado em: (2020-01-01)

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
por: Yuanquan Yang, et al.
Publicado em: (2022-08-01)

Fatal Case of Immune-Related Myocarditis and Myositis Due to Treatment with Immune Checkpoint and Tyrosine Kinase Inhibitors
por: João Queirós Coelho, et al.
Publicado em: (2024-10-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
por: Hor-Yue Tan, et al.
Publicado em: (2018-02-01)